Archon Biosciences
- Biotech or pharma, therapeutic R&D
Pioneering generative protein design (from the lab of 2024 Nobel Laureate, David Baker) delivers self-assembling, multi-valent/-specific Antibody Cages (AbCs - with 2-30 Ab), that are being developed as therapeutics (ADCs, agonists, TCEs, etc.) with differentiated biodistribution & target engagement.
Our pipeline leverages our AbCs' incredible avidity, payload capacity, structural control, and binding geometries in an incredibly modular, developable, and manufacturable way.
Preclinical Pipeline (oncology):
- ADCs
- Agonizers, receptor clustering, inhibition
- Multispecifics
)
)
){kind=logo}
){kind=logo}
){kind=logo}